Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: BWAC who wrote (2042)	7/21/1998 12:38:00 PM
From: Machaon	Respond to of 2553

<< Whats this 4 1/4 stuff. >> It's either us shareholders losing our arses, or a great buying opportunity! I just picked up some more @ 4 5/16. It's just my bet that the 2nd qtr earnings report is going to show that the Carticel business is getting into high growth gear. Is it, or isn't it going well? << Thank goodness for the positive article on Epicel. >> Up until the 1st quarter, Epicel hadn't been a major factor in GENZL's growth. The main emphasis of GENZL seems to be on Carticel. << Carticel seems to be ramping up well. Insurance companies are starting to accept the procedure. Doctors being trained. >> This is what I am betting on! << Could the stock price problem be related to Neurocell for Parkinsons? >> I don't know. GENZL is the first company to be approved, by the FDA, for Phase II trials in animal transplants (Xenotransplantation). The trials started in January. They had good results in the Phase I trials, and are using the fetal pig cells in "both" sides of the brain, instead of just the one side in the Phase I trials. It would definitely be bad if they had problems with their Phase II trials, but so far I've seen nothing negative about them. << Considering all this. I'm going to buy at 4 1/4 if it gets filled. >> Good luck with your bid. << They would exercise the buyback option soon if this price falls much farther. >> I hope not! Good luck, Bob